(Q48702586)

14 February 2018

title

Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. (English)

1 reference

14 February 2018

main subject

cost–benefit analysis

1 reference

2

1 reference

14 February 2018

author name string

Francis R

1

1 reference

14 February 2018

Brunström G

3

1 reference

14 February 2018

Holden L

4

1 reference

14 February 2018

Newlands ES

5

1 reference

14 February 2018

Rustin GJ

6

1 reference

14 February 2018

Seckl MJ

7

1 reference

14 February 2018

publication date

1 October 2000

1 reference

14 February 2018

European Journal of Cancer

published in

1 reference

14 February 2018

volume

36

1 reference

14 February 2018

issue

15

1 reference

14 February 2018

page(s)

1925-1932

1 reference

14 February 2018

Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Pilot Study to Evaluate Impact of a Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Evaluation of long-term toxicity after chemotherapy for testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Treatment of testicular cancer and the development of secondary malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Is routine pre-treatment cryopreservation of semen worthwhile in the management of patients with testicular cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Results of semen cryopreservation in young men with testicular carcinoma and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Sexuality and fertility in long-term survivors of testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Controversies in the management of testicular seminoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Stage I testicular seminoma: rationale for postorchiectomy radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

An analysis of surveillance for stage I combined teratoma--seminoma of the testis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Testicular germ-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Radiotherapy for stage I seminoma testis: results of treatment and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

Secondary neoplasms following treatment of malignant germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900140-4

7 January 2021

10.1016/S0959-8049(00)00140-4

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

11000572

1 reference

14 February 2018